Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

All participants also received standard care for MASH. Participants got two liver biopsies to help evaluate the effects of semaglutide. About 56% of participants had type 2 diabetes, and about 73% ...